Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.
Sign Up to like & getrecommendations! Published in 2018 at "Brachytherapy"
DOI: 10.1016/j.brachy.2017.11.007
Abstract: PURPOSE To compare quality of life (QoL) after brachytherapy with one of the three approved radioactive isotopes. METHODS AND MATERIALS Patients with mostly favorable intermediate-risk prostate cancer were treated on this prospective phase II trial… read more here.
Keywords: prostate; brachytherapy monotherapy; brachytherapy; prospective phase ... See more keywords
HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Brachytherapy"
DOI: 10.1016/j.brachy.2020.10.009
Abstract: PURPOSE The effectiveness and safety of high dose brachytherapy as monotherapy (HDR-BRT-M) in prostate cancer is limited to retrospective studies. We performed a meta-analysis to summarize existing data and identify trends in biochemical recurrence-free survival… read more here.
Keywords: brachytherapy monotherapy; hdr; analysis; prostate cancer ... See more keywords
Prostate cancer: Brachytherapy monotherapy is efficacious
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2017.195
Abstract: A randomized, open-label phase III trial of custirsen in 635 men with metastatic castration-resistant prostate cancer that had progressed after docetaxel showed no survival benefit for the addition of custirsen to cabazitaxel plus prednisone treatment.… read more here.
Keywords: brachytherapy monotherapy; prostate cancer; cancer brachytherapy; monotherapy efficacious ... See more keywords